Synthesis and pharmacological evaluation of pomalidomide derivatives useful for sickle cell disease treatment.

Synthesis and pharmacological evaluation of pomalidomide derivatives useful for sickle cell disease treatment.
复制标题

用于镰状细胞病治疗的泊马度胺衍生物的合成和药理学评价。

DOI:
10.1016/j.bioorg.2021.105077
复制
发表时间:
2021-09
影响因子:
5.1
通讯作者:
Dos Santos JL
Dos Santos JL
中科院分区:
化学1区
文献类型:
--
作者:
de Melo TRF;Dulmovits BM;Fernandes GFDS;de Souza CM;Lanaro C;He M;Al Abed Y;Chung MC;Blanc L;Costa FF;Dos Santos JL

文献摘要

参考文献

相似文献

胎儿血红蛋白 (HbF) 诱导是治疗镰状细胞病 (SCD) 症状的一种有价值且经过验证的方法。在这里,我们合成了泊马度胺-一氧化氮 (NO) 供体衍生物 (3a-f) 并评估了它们作为新型 HbF 诱导剂的适用性。所有化合物都表现出不同的释放 NO 的能力,范围为 0.3-30.3%。化合物3d是CD34+细胞最有效的HbF诱导剂,表现出与羟基脲相似的作用。我们通过研究转录因子(BCL11A、IKAROS 和 LRF)水平的体外变化、组蛋白脱乙酰酶(HDAC-1 和 HDAC-2)的抑制以及 cGMP 水平的测量,研究了化合物 3d 诱导 HbF 的作用模式。此外,化合物 3d 表现出与泊马度胺类似的有效抗炎作用,可将脂多糖处理的人单核细胞中的 TNF-α 水平降低高达 58.6%。化学水解研究表明,化合物 3d 在 pH 7.4 下稳定长达 24 小时。这些结果表明化合物 3d 是一种新型 HbF 诱导剂原型,具有治疗 SCD 症状的潜力。
Fetal hemoglobin (HbF) induction constitutes a valuable and validated approach to treat the symptoms of sickle cell disease (SCD). Here, we synthesized pomalidomide–nitric oxide (NO) donor derivatives (3a–f) and evaluated their suitability as novel HbF inducers. All compounds demonstrated different capacities of releasing NO, ranging 0.3–30.3%. Compound 3d was the most effective HbF inducer for CD34+ cells, exhibiting an effect similar to that of hydroxyurea. We investigated the mode of action of compound 3d for HbF induction by studying the in vitro alterations in the levels of transcription factors (BCL11A, IKAROS, and LRF), inhibition of histone deacetylase enzymes (HDAC-1 and HDAC-2), and measurement of cGMP levels. Additionally, compound 3d exhibited a potent anti-inflammatory effect similar to that of pomalidomide by reducing the TNF-α levels in human mononuclear cells treated with lipopolysaccharides up to 58.6%. Chemical hydrolysis studies revealed that compound 3d was stable at pH 7.4 up to 24 h. These results suggest that compound 3d is a novel HbF inducer prototype with the potential to treat SCD symptoms.
DOI: 10.1074/jbc.274.1.537
发表时间: 1999-01-01
影响因子: 4.8
作者:
Browning, DD;Windes, ND;Ye, RD
通讯作者: Ye, RD
DOI: 10.1182/blood-2007-07-098202
发表时间: 2008-02-01
期刊: BLOOD
影响因子: 20.3
作者:
Dijon, Marilyne;Bardin, Florence;Tonnelle, Cecile
通讯作者: Tonnelle, Cecile
DOI: 10.1016/j.bmc.2010.06.002
发表时间: 2010-07-15
影响因子: 3.5
作者:
Cupertino da Silva, Yolanda Karla;Augusto, Cristina Villarinho;Alexandre-Moreira, Magna Suzana
通讯作者: Alexandre-Moreira, Magna Suzana
DOI: 10.1111/j.1365-2141.2004.04810.x
发表时间: 2004-02-01
影响因子: 6.5
作者:
Conran, N;Oresco-Santos, C;Costa, FF
通讯作者: Costa, FF
DOI: 10.1021/ci300299n
发表时间: 2012-09-01
影响因子: 5.6
作者:
Blanco, Fernando;Egan, Billy;Lloyd, David G.
通讯作者: Lloyd, David G.